ClinicalTrials.gg
Active, not recruitingNCT05201638ENSURE-2Updated Oct 1, 2026

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

A Phase 3 interventional study of IMU-838 tablets and Placebo matching IMU-838 tablets in Multiple Sclerosis, Relapsing-Remitting, sponsored by Immunic AG. Active, not recruiting at 101 sites in 14 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Immunic AG · Phase 3, Interventional, and Treatment

How we know

Updated Oct 1, 2026First site in Russia30 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)

Read the detailed description

This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU-838 in adult patients with RMS.

The study will consist of the following periods:

Screening Period: Approximately 28 days Main Treatment Period: 72 weeks (approximately 15 months) Open Label Extension Period: Up to approximately 8 years

02

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting
03

In context

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

This study's enrollment of 1,100 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Lead sponsor

Immunic AG is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient (age ≥18 to ≤55 years).
  • Patients with an established diagnosis of MS according to 2017 McDonald Criteria.
  • Patients with RMS comprising of relapsing remitting MS (RRMS) and active secondary progressive MS, both defined according to Lublin criteria 1996 and 2014.
  • Active disease as defined by Lublin 2014 evidenced prior to Screening by:

    1. At least 2 relapses in the last 24 months before randomization, or
    2. At least 1 relapse in the last 12 months before randomization, or
    3. A positive Gd+ MRI scan (brain and/or spine) in the last 12 months prior to randomization.
  • Willingness and ability to comply with the protocol.
  • Written given prior to any study-related procedure.

Exclusion criteria

Exclusion Criteria:

  • Patients with non-active secondary progressive MS and primary progressive MS.
  • Any disease other than MS that may better explain the signs and symptoms, including history of complete transverse myelitis.
  • Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-IgG-associated encephalomyelitis
  • Any active and uncontrolled coexisting disease, other than MS (except for type 1 diabetes mellitus and inflammatory bowel disease)
  • Use of experimental/ drug (with the exception of COVID-19 vaccines approved by emergency use authorization) and/or participation in drug clinical studies within 6 months prior to Screening
  • Previous or current use of MS treatments lifelong, or within a pre-specified time period.
  • Use of the pre-specified concomitant medications.
  • Clinically significantly abnormal and pre-specified lab values.
  • History of chronic systemic infections within 6 months before the date of .
  • Diagnosis or suspected liver function impairment, which may cause fluctuating liver function tests during this study.
  • Known history of nephrolithiasis or underlying condition with a strong association of nephrolithiasis.
  • History or clinical diagnosis of gout.
  • History or presence of any major medical or psychiatric illness
  • Substantial medical condition that could create undue risk to the patient, could affect adherence with the study protocol or could undesirably affect study outcomes
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,100 participants (actual)

Study arms

  • Experimental
    IMU-838

    IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH. Formulation: Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning.

    Drug: IMU-838 tablets

  • Placebo comparator
    Placebo

    Matching placebo, as described for the test product, identical number of tablets as given for IMU-838.

    Drug: Placebo matching IMU-838 tablets

Interventions

  • DrugVidofludimus-calciumStudies of Vidofludimus-calciumVidofludimus-calcium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients are randomized to IMU-838 or placebo in ratio 1:1

    Also known as: Vidofludimus calcium

  • DrugPlacebo matching IMU-838 tablets

    Patients are randomized to IMU-838 or placebo in ratio 1:1

    Also known as: Placebo matching vidofludimus calcium

06

What researchers measure

Primary outcomes

  1. To evaluate efficacy of IMU-838 versus placebo based on time to first relapse

    Survival analysis of time to first relapse, occurred after the start of study treatment administration and before the end of the double-blind period, censored at a maximum of 72 weeks.

    Time frame: 72 weeks

Secondary outcomes

  1. Effect of IMU-838 versus placebo on volume of new T2 lesions

    To evaluate the effect of IMU-838 versus placebo on volume of new T2 lesions. Mean difference between IMU-838 and placebo in changes of the volume of new MRI T2 lesions over 24-weeks of treatment in the double-blind period.

    Time frame: 72 weeks

  2. Effect of IMU-838 versus placebo on disability progression

    To evaluate the effect of IMU-838 versus placebo on disability progression. Survival analysis of time to 12-week confirmed disability progression, as measured on Expanded Disability Status Scale during the double-blind period, censored at maximum 72-weeks.

    Time frame: 72 weeks

  3. Effect of IMU-838 versus placebo on cognitive performance

    To evaluate the effect of IMU-838 versus placebo on cognitive performance. Survival analysis of time to confirmed clinically relevant changes on Symbol Digit Modalities Test during the double-blind period, censored at maximum 72- weeks.

    Time frame: 72 weeks

  4. Effect of IMU-838 versus placebo on whole brain atrophy

    To evaluate the effect of IMU-838 versus placebo on whole brain atrophy. Difference in the mean of the percentage change on the whole brain volume between IMU-838 and placebo during the 72-weeks double-blind period.

    Time frame: 72 weeks

  5. Safety of IMU-838 versus placebo

    To evaluate safety and tolerability by assessment of occurrence of Adverse Events.

    Time frame: 72 weeks

07

Study locations

101 sites
  • Neuro of Central Florida
    Altamonte Springs, Florida 32714, United States
  • Healthcare Innovations
    Coral Springs, Florida 33067, United States
  • Heratsi Hospital Complex 1
    Yerevan, 0025, Armenia
  • Saint Gregory the Illuminator Medical Center
    Yerevan, 0056, Armenia
  • Erebouni Medical Center
    Yerevan, 0087, Armenia
  • UCC of Rep of Srpska
    Banja Luka, Bosnia and Herzegovina
  • Cantonal Hospital Bihac Dr. Irfan Ljubijankic
    Bihać, 77000, Bosnia and Herzegovina
  • University Clinical Hospital Mostar
    Mostar, 88000, Bosnia and Herzegovina
  • University Clinical Center of Sarajevo
    Sarajevo, 71000, Bosnia and Herzegovina
  • University Clinical Center Sarajevo
    Sarajevo, 71000, Bosnia and Herzegovina
  • University Clinical Center Tuzla
    Tuzla, 75000, Bosnia and Herzegovina
  • Astra Clinic
    Tallinn, Estonia
  • University Hospital Muenster, Institute Translational Neurology dept. Neurology
    Münster, 48149, Germany
  • Post-Graduation Institute of Medical Education and Research (PGIMER)
    Chandigarh, 160012, India
  • North East Healthcare Pvt Ltd (Marengo Asia Hospitals, Gurugram)
    Haryāna, 122011, India
  • Dr Ram Manohar Lohia Institute of Medical Sciences
    Lucknow, 226010, India
  • All India Institute of Medical Sciences
    New Delhi, 110029, India
  • GB Pant Institute of Postgraduate Medical Education and Research
    New Delhi, 110056, India
  • SRI Guru Ram Das Institute of Medical Sciences and Research
    Punjābi Bāgh, 143006, India
  • Vasudev Multi-Speciality Hospital
    Raipur, 492013, India
  • Hospital Nacional Dos de Mayo
    Lima, 15003, Peru
  • NZOZ Novo-Med
    Katowice, 40-584, Poland
  • NZOZ Wielospecjalistyczna Poradnia Lekarska "Synapsis"
    Katowice, 40123, Poland
  • Neuro-Medic Janusz Zbrojkiewicz
    Katowice, 40686, Poland
  • NZOZ Neuromed
    Lublin, 20-064, Poland
  • Indywidualna Praktyka Lekarska prof. Konrad Rejdak
    Lublin, 20-410, Poland
  • NZOZ Hertmanowskiej
    Plewiska, 62-064, Poland
  • NZOZ Neuro-Kard
    Poznan, 61-853, Poland
  • Centrum Medyczne NeuroProtect
    Warsaw, 01684, Poland
  • Centrum Med. Ibismed
    Zabrze, Poland
  • Clubul Sanatatii SRL
    Campulung Muscel, 115100, Romania
  • Spitalul clinic CF Constanta
    Constanța, 900123, Romania
  • Spitalul Judetean de Urgenta Piatra Neamt
    Piatra Neamţ, 610136, Romania
  • Aria Clinic SRL
    Sibiu, 550052, Romania
  • Arkhangelsk Regional Clinical Hospital
    Arkhangelsk, 163045, Russia
  • Kazan State Medical Academy (Polyclinic) / Federal State Budgetary Educational Institution of Supplementary Professional Education "Russian medical academy of continuous professional education" of the Ministry of Health of the Russian Federation
    Kazan', 420061, Russia
  • Kuzbass regional clinical hospital n.a. S.V.Belyaev
    Kemerovo, 650066, Russia
  • Budgetary Institution of Khanty-Mansiysk Autonomous District-Yugra "Regional Clinical Hospital"
    Khanty-Mansiysk, 628012, Russia
  • Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Healthcare of the Russian Federation
    Kirov, 610998, Russia
  • State Budgetary healthcare Institution of Moscow City "City Policlinic 2 of the Healthcare Department of Moscow City"
    Moscow, 117556, Russia
  • First Moscow State Medical University n.a. I.M. Sechenov
    Moscow, 119021, Russia
  • Federal Scientific Clinical Centre of Physical-Chemical Medicine of the Federal Medial Biological Agency
    Moscow, 119992, Russia
  • Russian Сenter of Neurology and Neurosciences, RCNN;
    Moscow, 125367, Russia
  • Privolzhsky Federal Medical University of Ministry of Health of the Russian Federation
    Nizhny Novgorod, 603155, Russia
  • Siberian District Medical Center
    Novosibirsk, 630007, Russia
  • Rostov State Medical Unevrsity
    Rostov-on-Don, 344022, Russia
  • LLC Praximed
    Saint Petersburg, 194223, Russia
  • Leningrad Regional Hospital
    Saint Petersburg, 194291, Russia
  • 1st St Petersburg State Medical University
    Saint Petersburg, 197022, Russia
  • St. Petersburg State Budgetary Healthcare Institution "City Clinical Hospital No. 31"
    Saint Petersburg, 197110, Russia
  • Institute of the human brain of the Russian Academy of Sciences n.a. N.P. Bekhtereva
    Saint Petersburg, 197376, Russia
  • City Hospital 40
    Saint Petersburg, 197706, Russia
  • Samara regional clinical hospital n. a. V. L. Seredavin
    Samara, 443095, Russia
  • Republican Clinical Hospital #4
    Saransk, 430032, Russia
  • Smolensk Regional Clinical Hospital
    Smolensk, 214019, Russia
  • Nebbiolo Center for Clinical Trials
    Tomsk, 634009, Russia
  • Medical Unit "Neftianik"
    Tyumen, 625048, Russia
  • Republican Clinical Hospital named after G.G. Kuvatov
    Ufa, 450005, Russia
  • Ulyanovsk regional clinical hospital
    Ulyanovsk, 432017, Russia
  • Klinicko bolnicki centar Dr Dragisa Misovic - Dedinje
    Belgrade, 11000, Serbia
  • Klinicko bolnicki centar Zvezdara
    Belgrade, 11000, Serbia
  • Vojnomedicinska akademija
    Belgrade, 11000, Serbia
  • Univerzitetski Klinicki centar Kragujevac
    Kragujevac, 34000, Serbia
  • General Hospital Leskovac
    Leskovac, 16000, Serbia
  • Univerzitetski Klinicki centar Nis
    Niš, 18000, Serbia
  • Hsptl Sveti Vracevi
    Novi Kneževac, Serbia
  • General Hospital Uzice
    Užice, 31000, Serbia
  • Klinicko Bolnicki centar Zemun
    Zemun, 11080, Serbia
  • Opsta bolnica Djordje Jovanovic Zrenjanin
    Zrenjanin, 23000, Serbia
  • Adana Baskent Hospital
    Adana, 01250, Turkey (Türkiye)
  • Uludag University Hospital
    Bursa, 16059, Turkey (Türkiye)
  • Bursa Yuksek Ihtisas Eğitim Ve Araştırma Hastanesi
    Bursa, 16140, Turkey (Türkiye)
  • Bezmialem Vakif University Hospital
    Istanbul, 34093, Turkey (Türkiye)
  • T.C. Ministry of Health Istanbul Haseki Training and Research Hospital
    Istanbul, 34250, Turkey (Türkiye)
  • Sancaktepe Sehit Prof.Dr. Ilhan Varank Training and Research Hospital
    Istanbul, 34785, Turkey (Türkiye)
  • Haydar Pasa Num. EAH
    Istanbul, Turkey (Türkiye)
  • Kocaeli University Research and Application Hospital
    Kocaeli, 41000, Turkey (Türkiye)
  • Kutahya Uni Evliya Celebi Hspt
    Kütahya, 43040, Turkey (Türkiye)
  • Manisa Celal Bayar University Hafsa Sultan Hospital
    Manisa, 45030, Turkey (Türkiye)
  • Sakarya Egitim ve Arastirma Hast
    Sakarya, 54100, Turkey (Türkiye)
  • 19 Mayis University Medical Faculty Hospital Health Application and Research Center
    Samsun, 55200, Turkey (Türkiye)
  • Namik Kemal Uni Hospital
    Tekirdağ, 59100, Turkey (Türkiye)
  • Communal noncommercial enterprise "First Cherkasy City Hospital"
    Cherkasy, 18009, Ukraine
  • MS Diagnosis Treatment Center
    Cherkasy, Ukraine
  • Chernihiv City Hospital 4
    Chernihiv, Ukraine
  • Municipal Institution "Dnipropetrovsk Regional Rehabilitation Hospital" of Dnipropetrovsk Regional Council"
    Dnipro, 49000, Ukraine
  • Ukrainian State Research Institute of Medico-Social Problems of Disability
    Dnipro, 49027, Ukraine
  • "University Clinic" of Dnipro State Medical University, Department of Neurology
    Dnipro, 49038, Ukraine
  • Dnipro City Hospital 6
    Dnipro, Ukraine
  • Communal Non-Commercial Medical Enterprise "O.T.Bohayevskyi Kremenchuk City Hospital #1
    Kremenchuk, 39623, Ukraine
  • State Institution "National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine
    Kyiv, 03115, Ukraine
  • 1 Private Clinic Medical Center
    Kyiv, Ukraine
  • Dopomoga Plus medical center
    Kyiv, Ukraine
  • Volyn Reg Clin Hospital
    Lutsk, 43005, Ukraine
  • Lviv Regional Central Hospital
    Lviv, 79010, Ukraine
  • 5 City Clin Hospital
    Lviv, 79013, Ukraine
  • Communal institution "City Clinical Hospital №3" of Poltava City Council
    Poltava, 36000, Ukraine
  • City Clinical Hospital 2
    Rivne, Ukraine
  • Sumy Reg Clinical Hospital
    Sumy, Ukraine
  • Salutem
    Vinnytsia, 21018, Ukraine

Showing the first 100 of 101 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Nov 2026, 58 months after the start.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 58 months is above that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Jan 21, 2022
StartActual
Jan 12, 2022
Primary completionEst.
Nov 2026
CompletionEst.
Oct 2033
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
30 sites added, 5 sites removed — first site in Russia
Show 30 added (25 Russia, 2 India, 1 Bosnia and Herzegovina, 1 Romania, 1 Turkey (Türkiye))
  • University Clinical Hospital Mostar · Mostar, Bosnia and Herzegovina
  • North East Healthcare Pvt Ltd (Marengo Asia Hospitals, Gurugram) · Haryāna, India
  • Vasudev Multi-Speciality Hospital · Raipur, India
  • Spitalul Judetean de Urgenta Piatra Neamt · Piatra Neamţ, Romania
  • Arkhangelsk Regional Clinical Hospital · Arkhangelsk, Russia
  • Kazan State Medical Academy (Polyclinic) / Federal State Budgetary Educational Institution of Supplementary Professional Education "Russian medical academy of continuous professional education" of the Ministry of Health of the Russian Federation · Kazan', Russia
  • Kuzbass regional clinical hospital n.a. S.V.Belyaev · Kemerovo, Russia
  • Budgetary Institution of Khanty-Mansiysk Autonomous District-Yugra "Regional Clinical Hospital" · Khanty-Mansiysk, Russia
  • Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Healthcare of the Russian Federation · Kirov, Russia
  • State Budgetary healthcare Institution of Moscow City "City Policlinic 2 of the Healthcare Department of Moscow City" · Moscow, Russia
  • First Moscow State Medical University n.a. I.M. Sechenov · Moscow, Russia
  • Federal Scientific Clinical Centre of Physical-Chemical Medicine of the Federal Medial Biological Agency · Moscow, Russia
  • Russian Сenter of Neurology and Neurosciences, RCNN; · Moscow, Russia
  • Privolzhsky Federal Medical University of Ministry of Health of the Russian Federation · Nizhny Novgorod, Russia
  • Siberian District Medical Center · Novosibirsk, Russia
  • Rostov State Medical Unevrsity · Rostov-on-Don, Russia
  • LLC Praximed · Saint Petersburg, Russia
  • Leningrad Regional Hospital · Saint Petersburg, Russia
  • 1st St Petersburg State Medical University · Saint Petersburg, Russia
  • St. Petersburg State Budgetary Healthcare Institution "City Clinical Hospital No. 31" · Saint Petersburg, Russia
  • Institute of the human brain of the Russian Academy of Sciences n.a. N.P. Bekhtereva · Saint Petersburg, Russia
  • City Hospital 40 · Saint Petersburg, Russia
  • Samara regional clinical hospital n. a. V. L. Seredavin · Samara, Russia
  • Republican Clinical Hospital #4 · Saransk, Russia
  • Smolensk Regional Clinical Hospital · Smolensk, Russia
  • Nebbiolo Center for Clinical Trials · Tomsk, Russia
  • Medical Unit "Neftianik" · Tyumen, Russia
  • Republican Clinical Hospital named after G.G. Kuvatov · Ufa, Russia
  • Ulyanovsk regional clinical hospital · Ulyanovsk, Russia
  • Bursa Yuksek Ihtisas Eğitim Ve Araştırma Hastanesi · Bursa, Turkey (Türkiye)
Show 5 removed
  • Fortis Memorial Research Institute · Gurugramam, India
  • Polakulath Narayanan Renai Medicity MSSH · Kochi, India
  • DKS PGI · Raipur, India
  • Instytut Zdrowia Boczarska · Oświęcim, Poland
  • FutureMeds Warszawa Centrum · Warsaw, Poland
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    30 sites added, 5 sites removed — first site in Russia
    Show 30 added (25 Russia, 2 India, 1 Bosnia and Herzegovina, 1 Romania, 1 Turkey (Türkiye))
    • University Clinical Hospital Mostar · Mostar, Bosnia and Herzegovina
    • North East Healthcare Pvt Ltd (Marengo Asia Hospitals, Gurugram) · Haryāna, India
    • Vasudev Multi-Speciality Hospital · Raipur, India
    • Spitalul Judetean de Urgenta Piatra Neamt · Piatra Neamţ, Romania
    • Arkhangelsk Regional Clinical Hospital · Arkhangelsk, Russia
    • Kazan State Medical Academy (Polyclinic) / Federal State Budgetary Educational Institution of Supplementary Professional Education "Russian medical academy of continuous professional education" of the Ministry of Health of the Russian Federation · Kazan', Russia
    • Kuzbass regional clinical hospital n.a. S.V.Belyaev · Kemerovo, Russia
    • Budgetary Institution of Khanty-Mansiysk Autonomous District-Yugra "Regional Clinical Hospital" · Khanty-Mansiysk, Russia
    • Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Healthcare of the Russian Federation · Kirov, Russia
    • State Budgetary healthcare Institution of Moscow City "City Policlinic 2 of the Healthcare Department of Moscow City" · Moscow, Russia
    • First Moscow State Medical University n.a. I.M. Sechenov · Moscow, Russia
    • Federal Scientific Clinical Centre of Physical-Chemical Medicine of the Federal Medial Biological Agency · Moscow, Russia
    • Russian Сenter of Neurology and Neurosciences, RCNN; · Moscow, Russia
    • Privolzhsky Federal Medical University of Ministry of Health of the Russian Federation · Nizhny Novgorod, Russia
    • Siberian District Medical Center · Novosibirsk, Russia
    • Rostov State Medical Unevrsity · Rostov-on-Don, Russia
    • LLC Praximed · Saint Petersburg, Russia
    • Leningrad Regional Hospital · Saint Petersburg, Russia
    • 1st St Petersburg State Medical University · Saint Petersburg, Russia
    • St. Petersburg State Budgetary Healthcare Institution "City Clinical Hospital No. 31" · Saint Petersburg, Russia
    • Institute of the human brain of the Russian Academy of Sciences n.a. N.P. Bekhtereva · Saint Petersburg, Russia
    • City Hospital 40 · Saint Petersburg, Russia
    • Samara regional clinical hospital n. a. V. L. Seredavin · Samara, Russia
    • Republican Clinical Hospital #4 · Saransk, Russia
    • Smolensk Regional Clinical Hospital · Smolensk, Russia
    • Nebbiolo Center for Clinical Trials · Tomsk, Russia
    • Medical Unit "Neftianik" · Tyumen, Russia
    • Republican Clinical Hospital named after G.G. Kuvatov · Ufa, Russia
    • Ulyanovsk regional clinical hospital · Ulyanovsk, Russia
    • Bursa Yuksek Ihtisas Eğitim Ve Araştırma Hastanesi · Bursa, Turkey (Türkiye)
    Show 5 removed
    • Fortis Memorial Research Institute · Gurugramam, India
    • Polakulath Narayanan Renai Medicity MSSH · Kochi, India
    • DKS PGI · Raipur, India
    • Instytut Zdrowia Boczarska · Oświęcim, Poland
    • FutureMeds Warszawa Centrum · Warsaw, Poland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05201638
Lead sponsor
Immunic AG
Responsible party
Sponsor
First posted
Jan 21, 2022
Start date
Jan 12, 2022
Primary completion
Nov 2026 (estimated)
Completion
Oct 2033 (estimated)
Last update
Oct 1, 2026

Study contacts

Robert J. Fox, MD
principal investigator · Mellen Center for MS, Neurological Institute, Cleveland Clinic, Ohio

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vidofludimus-calcium

Start the discussion